Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients

Anticancer Research

Volumn 19, Issue 4 A, 1999, Pages 2523-2526

  Van Dalen, A ^a,l   Favier, J ^a   Baumgartner, L ^b   Hasholzner, U ^b   De Bruijn, H ^c   Dobbler, D ^d   Dombi, V H ^d   Fink, D ^d   Giai, M ^e   Mcging, P ^e   Harlozinska, A ^f   Kainz, Ch ^g   Markowska, J ^h   Molina, R ⁱ   Sturgeon, C ^j   Einarsson, R ^k  

^a GROENE HART HOSPITAL   (Netherlands)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e University of Medicine ^*

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^k BEKI Diagnostics   (Sweden)

^l Institute of Tumor Marker Oncology   (Netherlands)

more..

Author keywords

CA 125; Ovarian cancer; Prognosis; TPS

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOKERATIN; CYTOKERATIN 18; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; CARCINOMA; CYCLOPHOSPHAMIDE; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PEPTIDES; PROGNOSIS; PROSPECTIVE STUDIES; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032781042     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (6)

1. Mackay EV, Khoo SK, Daunter B. Tumor markers. In: Gynecologic Oncology. Churchill Livingson, New York, 1992.
2. Kenemans P, Bast RC, Yedema CA, Price MR, Hilgers J: CA 125 and polymorphic epethilial mucin as serum tumor markers. Cancer Rev 11-12: 119-144, 1988.
3. Pietrzak K, Zielinski J, Bidzinski M, Drabik M, Borowiak J, Sobiczewski P, Kaminska G, Zolciak A.: The evaluation of prognostic factors influencing the results, of the treatment of patients with ovarian cancer. In: 10th International Meeting of Gynaecological Oncology. Eds. C.F. de Oliveira and H. M. Oliveira. Monduzzi Editore, Bologna, 1997, pp 279-283.
4. Devine PL, McGuckin MA, Quin RJ, Ward BG: Predictive value of the combination of serum markers, CA 125, CASA and TPS in ovarian cancer. Int J Gyn Cancer 5: 170-178, 1995.
5. Dalen A van, Favier, J: CA 125 and TPS in the management of ovarian cancer patients. Presented at: CA 125 -Ten Years Later. San Remo, 1993. In: TPS: a Collection of Scientific Abstracts. Bromma, BEKI Diagnostics.
6. Dalen A van, Baumgartner L, Bruijn H de, Dornbi VH, Fink D, Giai M, McGing P, Hasholzner U, Harlozinska A, Kainz Ch, Markowska J, Molina R, Sturgeon C, Einarsson R: Prognostic significance of combined CA 125 and TPS levels after chemotherapy in ovarian cancer patients. Preliminary results of a multicenter study. In: 10th International Meeting of Gynaecological Oncology. Eds. C.F. de Oliveira and H.M. Oliveira. Monduzi Editore, Bologna, 1997, pp 291-295.